Stoke Therapeutics’ (STOK) Buy Rating Reiterated at BTIG Research

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a note issued to investors on Thursday,Benzinga reports. They currently have a $39.00 target price on the stock. BTIG Research’s price target indicates a potential upside of 25.73% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Guggenheim began coverage on Stoke Therapeutics in a research note on Thursday, February 5th. They set a “buy” rating and a $60.00 target price for the company. Wolfe Research initiated coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective for the company. Needham & Company LLC raised their price objective on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Chardan Capital reissued a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Canaccord Genuity Group increased their target price on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $39.83.

Stoke Therapeutics Trading Down 5.6%

Shares of Stoke Therapeutics stock opened at $31.02 on Thursday. The company has a market cap of $1.83 billion, a PE ratio of 46.30 and a beta of 1.07. The company has a 50 day moving average of $32.61 and a 200-day moving average of $29.90. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $40.22.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Arthur Tzianabos sold 4,355 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $40.00, for a total transaction of $174,200.00. Following the sale, the insider directly owned 31,339 shares of the company’s stock, valued at $1,253,560. The trade was a 12.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Adrian R. Krainer sold 33,243 shares of the firm’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the transaction, the director directly owned 283,302 shares of the company’s stock, valued at $11,258,421.48. The trade was a 10.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 38,203 shares of company stock valued at $1,517,541 in the last ninety days. 9.50% of the stock is currently owned by insiders.

Institutional Trading of Stoke Therapeutics

Institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Stoke Therapeutics by 5.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after purchasing an additional 1,149 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Stoke Therapeutics by 21.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after buying an additional 293,072 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Stoke Therapeutics by 125.2% in the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after buying an additional 15,001 shares during the period. Geode Capital Management LLC raised its position in shares of Stoke Therapeutics by 7.9% during the second quarter. Geode Capital Management LLC now owns 972,921 shares of the company’s stock worth $11,044,000 after acquiring an additional 70,935 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its position in shares of Stoke Therapeutics by 33.2% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after acquiring an additional 2,384 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.